Relapses in hepatoblastoma patients: clinical characteristics and outcome--experience of the International Childhood Liver Tumour Strategy Group (SIOPEL).

[1]  M. Stevens,et al.  Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Perilongo,et al.  Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B. Morland,et al.  Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. , 2009, The New England journal of medicine.

[4]  G. Perilongo,et al.  Autologous peripheral blood stem‐cell transplantation with a double‐conditioning regimen for recurrent hepatoblastoma after liver transplantation – A valid therapeutic option or just too much? , 2009, Pediatric Transplantation.

[5]  N. Radlović,et al.  [Successful treatment of second hepatoblastoma relapse--case report]. , 2009, Acta chirurgica iugoslavica.

[6]  Q. Shu,et al.  Percutaneous radiofrequency ablation for treatment of hepatoblastoma recurrence , 2008, Pediatric Radiology.

[7]  Zhengjia Chen,et al.  Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  O. Ijichi,et al.  Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single‐agent therapy with irinotecan , 2006, Pediatric transplantation.

[9]  C. Jones,et al.  The hook effect: a need for constant vigilance , 2006, Annals of clinical biochemistry.

[10]  A. Zimmermann.  The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis. , 2005, European journal of cancer.

[11]  G. Perilongo,et al.  Phase II study of high-dose cyclophosphamide in relapsing and/or resistant hepatoblastoma in children: a study from the SIOPEL group. , 2004, European journal of cancer.

[12]  G. Perilongo,et al.  Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2. , 2004, European journal of cancer.

[13]  Denise Williams,et al.  Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11). , 2003, Medical and pediatric oncology.

[14]  H. Mugishima,et al.  Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma , 2003, Pediatric Surgery International.

[15]  J. Feusner,et al.  Small cell undifferentiated histology in hepatoblastoma may be unfavorable , 2001 .

[16]  G. Perilongo,et al.  Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Perilongo,et al.  SIOPEL trials using preoperative chemotherapy in hepatoblastoma. , 2000, The Lancet. Oncology.

[18]  D. V. von Schweinitz,et al.  Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: A report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94 , 1999, Klinische Padiatrie.

[19]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[20]  N. Breslow,et al.  Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.